МЕТФОРМИН - НАДЕЖНЫЙ ПАРТНЕР В ЛЕЧЕНИИ ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В лечении сахарного диабета (СД) 2 типа важную роль играет воздействие на ключевое патогенетическое звено в развитии заболевания - инсулинорезистентность. С этой целью уже более 50 лет в медицинской практике применяются бигуаниды, в частности метформин. В обзоре представлены данные литературы о роли метформина в лечении СД2. Обсуждены различные эффекты препарата на гликемический контроль, влияние на сердечно-сосудистую систему, липидный обмен, гемостаз, антиоксидантную систему, а также опыт и результаты применения в акушерстве и гинекологии. Особое внимание уделено противораковым эффектам метформина. Рассмотрен один из представителей препарата метформина - Глюкофаж.

Полный текст

Доступ закрыт

Об авторах

Н. А Петунина

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Email: napetunina@mail.ru
д.м.н., проф., зав. кафедрой эндокринологии

И. А Кузина

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России

старший лаборант кафедры эндокринологии

Список литературы

  1. Godarzi M.O., Brier-Ash M. Metformin revisited: revaluation of its properties and the pharmacopoeia of modern sntidiabetic agents. Diabetes Obes. Metab. 2005; 5: 654-65.
  2. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996; 334: 574-79.
  3. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-53.
  4. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35.
  5. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-74.
  6. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012; 13: 251-62.
  7. Shaw R.J., Lamia K.A., Vasquez D. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310: 1642-46.
  8. El-Mir M.Y., Nogueira V., Fontaine E. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000; 275; 223-28.
  9. Genuth S. The UKPDS and its global impact. Diabet Med. 2008; 25(2): 57-62.
  10. Chau-Van C., Gamba M., Salvi R., et al. Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology. 2007; 148(2): 507-11.
  11. Glueck C.J., Fontaine R.N., Wang P. Metformin reduces weight, centripetalobesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001; 50: 856-61.
  12. Eleftheriadou I., Grigoropoulou P., Katsilambros N., Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr. Diabet. Rev. 2008; 4: 340-56.
  13. Erdmann E. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int. J. Cardiol. 2006; 107: 147-53.
  14. Aguayo Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome. 2013; 5: 6.
  15. Мкртумян А.М., Бирюкова Е.В. Метформин -единственный бигуанид с широким спектром действия, рекомендованный IDF как препарат первого ряда выбора. Русский медицинский журнал. 2006; 14(27): 1991-96.
  16. Isoda K., Young J., Zirlik A. Metformin inhibits Proinflammatory Responses and Nuclear Factor in Human Vascular Wall Cells. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 611-17.
  17. The Diabetes Prevention Program Research Group Intensive: Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance. Diabetes. 2005; 54(5): 1566-72.
  18. Faure P., Rossini E., Wiernsperger N. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes. 1999; 48: 353-57.
  19. Beisswenger P., Rugiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab. 2003; 29(6S): 95-103.
  20. Anedda A., Rial E., Gonzalez B. Metformin induces oxidative stress in white adipocytes and raises uncoupling proten levels. J. Endocrinol. 2008; 199: 33-40.
  21. Zheng Z., Chen H., Li J., et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012; 61(1): 217-28.
  22. Lily M., Godwin M. Treating prediabetes with metformin systematic review and meta-analysis. Can. Fam. Physician. 2009; 55: 363-69.
  23. Desilets A.R., Dhakal-Karki S., Dunican K.C. Role of metformin for weight management in patients without type 2 diabetes. Ann. Pharmacother. 2008; 42: 817-26.
  24. Kusaka I., Nagasaka S., Horie H., Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes. Metab. 2008; 10: 1039-46.
  25. Mannucci E., Ognibene A., Cremasco F. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001; 24: 489-94.
  26. Boussageon R., Supper I., Bejan-Angoulvant T. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoSMed. 2012; 9(4): e1001204.
  27. MacDonald M.R., Petrie M.C., Hawkins N.M. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur. Heart J. 2008; 10: 1224-40.
  28. Hulisz D.T., Bonfiglio M.F., Murray R.D. Metformin-associated lactic acidosis. J. Am. Board. Fam. Pract. 1998; 11: 233-36.
  29. Papanas N., Maltezos E., Mikhailidis D.P. Metformin and heart failure: never say never again. Expert Opin. Pharmacother. 2012; 1: 1-8.
  30. Rachmani R., Slavachevski I., Levi Z., Zadok B., Kedar Y., Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur. J. Intern. Med. 2002; 13: 428-33.
  31. Chen S.Q., Liu Q., Sun H., Tang L., Deng J.C. Effects of metformin on fatty liver in insulin-resistant rats. ZhonghuaGanZang Bing ZaZhi. 2005; 13(12): 915-18.
  32. Diamanti-Kandarakis E., Christakou C.D., Kandaraki E., Economou F.N. Metformin: an old medication of new fation: evolving new molecular mechanism and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol. 2010; 162(2): 193-212.
  33. Glueck C.J., Goldenberg N.,Wang P., Loftspring M., Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Human Reproduction. 2004; 19: 3: 510-21.
  34. Genazzani A.D., Ricchieri F., Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (LondEngl). 2010; 6(4): 577-93.
  35. Kovo M., Weissman A., Gur D. et al. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J. Matern. Fetal. Neonat. Med. 2006; 19: 415-19.
  36. Dowling R., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine. 2011; 9: 33.
  37. Li D., Yeung S.J., Hassan M.M., Konopleva M., Abbruzzese J.L. Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137(2): 482-88.
  38. Donadon V., Balbi M., Valent F., Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J. Gastroenterol. 2010; 16(24): 3025-32.
  39. Landman G.W., Kleefstra N., van Hateren K.J. Metformin associated with lower cancer mortality in type 2 diabetes ZODIAC-16. Diabetes Care. 2010; 33: 322-26.
  40. Lee J.H., Kim T.I., Jeon S.M. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int. J. Cancer. 2011; 12: 1-24.
  41. Libby G., Donnelly L.A., Donnan P.T. New users of metformin area at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-25.
  42. Hosono K., Endo H., Takahashi H., Sugiyama M., Sakai E., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila). 2010; 3: 1077-83.
  43. Niraula S., Stambolic V., Dowling R.J.O., et al. Clinical and biologic effects of metformin in early stage breast cancer. Cancer Res. 2010; 70(24): 104s.
  44. Hadad S.M., Dewar J.A., Elseedawy E., et al. Gene Signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. J. Clin. Oncol. 2010; 28: 560.
  45. Hirsh H., Iliopoulos D., Tsichlis P., Stuh K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69(19): 7507-11.
  46. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; 1: CD002967.
  47. Tahrani A.A., Varghese G.I., Scarpello J.H., Hanna F.W.F. Metformin, heart failure and lactic acidosis: is Metformin absolutely contraindicated? BMJ. 2007; 355: 508-12.
  48. Bauman W.A., Shaw S., Jayatilleke E. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000; 23: 1227-31.
  49. Jager J., Kooy A., Lehert P., Wulffel M. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled trial. BMJ.2010; 340: c2181.
  50. Wei Ting R.Z., Szeto C.C., Chan M., Ma K. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Arch Intern. Med. 2006; 166: 1975-79.
  51. Desilets D.J., Shorr A.F., Moran K.A., Holtzmuller K.C. Cholestatic jaundice associated with the use of metformin. Am. J. Gastroenterol. 2001; 96: 2257-58.
  52. Kashyap A.S., Kashyap S. Haemolytic anaemia due to metformin. Postgrad Med. J. 2000; 76: 125-26.
  53. Blonde L., et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr. Med. Res. Opinm. 2004; 20(4): 565-72.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2014

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах